Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Leukemia
-
-
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
-
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia
-
Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia
-
Newly Activated Alliance Trials
E-News – June 2026Alliance Research Update Recently Activated Alliance Trials The Alliance for Clinical Trials in Oncology has recently launched several new clinical trials exploring targeted radiation therapy, improved treatment strategies and other innovative approaches to cancer care. From testing new radiation therapy techniques for lung cancer to treatments for breast cancer side effects, these trials…
-
Highlighting Alliance Progress and Impact in Research through News Reports
Highlighting Alliance Progress and Impact in Research through News Reports At the Alliance for Clinical Trials in Oncology, we love sharing stories that show what’s happening in cancer research right now. Whether it’s a new clinical trial, a scientific breakthrough, or the work of one of our dedicated investigators, we want people to see the…
-
Alliance Marks Adolescent and Young Adult Cancer Awareness Week
Each year, about 85,000 adolescents and young adults (AYA) between the ages of 15 and 39 are diagnosed with cancer in the United States. According to the National Cancer Institute, this represents about 4% of all new cancer diagnoses. Depending on age and specific diagnosis, many AYA people with cancer may be treated at either…
-
Alliance Trial Aims to Improve Outcomes for Chronic Lymphocytic Leukemia
The Alliance for Clinical Trials in Oncology has launched a new clinical trial for adults who need first-line therapy for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study (Alliance A042302) will explore whether combining two targeted medicines, zanubrutinib and sonrotoclax, can effectively send cancer into remission, allowing patients to discontinue treatment until…
Categories
Alliance Committee
Browse by Year